A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: Analysis by DMET microarray profiling

British Journal of Haematology

Volumn 154, Issue 4, 2011, Pages 529-533

  di Martino, Maria T ^a   Arbitrio, Mariamena ^b   Guzzi, Pietro H ^a   Leone, Emanuela ^a   Baudi, Francesco ^a   Piro, Eugenio ^c   Prantera, Tullia ^d   Cucinotto, Iole ^a   Calimeri, Teresa ^a   Rossi, Marco ^a   Veltri, Pierangelo ^a   Cannataro, Mario ^a   Tagliaferri, Pierosandro ^a   Tassone, Pierfrancesco ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^c PUGLIESE CIACCIO HOSPITAL   (Italy)

^d Ospedale San Giovanni di Dio   (Italy)

Author keywords

DMET; Multiple myeloma; Osteonecrosis of the jaw; PPARG; Zoledronic acid

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ZOLEDRONIC ACID;

3' UNTRANSLATED REGION; ADULT; AGED; BONE DISEASE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; JAW OSTEONECROSIS; LETTER; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; DIPHOSPHONATES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMIDAZOLES; JAW DISEASES; MIDDLE AGED; MULTIPLE MYELOMA; OSTEONECROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA;

EID: 79960838263     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08622.x     Document Type: Letter

References (10)

1. Ackert-Bicknell, C.L., Demissie, S., Marín de Evsikova, C., Hsu, Y.H., DeMambro, V.E., Karasik, D., Cupples, L.A., Ordovas, J.M., Tucker, K.L., Cho, K., Canalis, E., Paigen, B., Churchill, G.A., Forejt, J., Beamer, W.G., Ferrari, S., Bouxsein, M.L., Kiel, D.P. & Rosen, C.J. (2008) PPARG by dietary fat interaction influences bone mass in mice and humans. Journal of Bone and Mineral Research, 23, 1398-1408.
2. Dallongeville, J., Iribarren, C., Ferrières, J., Lyon, L., Evans, A., Go, A.S., Arveiler, D., Fortmann, S.P., Ducimetière, P., Hlatky, M.A., Amouyel, P., Southwick, A., Quertermous, T. & Meirhaeghe, A. (2009) Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease. PPAR Research, 2009, 11, doi: 10.1155/2009/543746.
3. Deeken, J. (2009) The Affymetrix DMET platform and pharmacogenetics in drug development. Current Opinion in Molecular Therapeutics, 11, 260-268.
4. Filleul, O., Crompot, E. & Saussez, S. (2010) Bisphosphonate-induced osteonecrosis of the jaw: a review of 2, 400 patient cases. Journal of Cancer Research and Clinical Oncology, 136, 1117-1124.
5. Garcia-Bates, T.M., Bernstein, S.H. & Phipps, R.P. (2008) Peroxisome proliferator-activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells. Clinical Cancer Research, 14, 6414-6425.
6. Kim, T.H., Hong, J.M., Park, E.K. & Kim, S.Y. (2007) Peroxisome proliferator-activated receptor-gamma gene polymorphisms are not associated with osteonecrosis of the femoral head in the Korean population. Molecules and Cells, 24, 388-393.
7. Rosen, E.D. & Spiegelman, B.M. (2001) PPARgamma a nuclear regulator of metabolism, differentiation, and cell growth. Journal of Biological Chemistry, 276, 37731-37734.
8. Sarasquete, M.E., García-Sanz, R., Marín, L., Alcoceba, M., Chillón, M.C., Balanzategui, A., Santamaria, C., Rosiñol, L., de la Rubia, J., Hernandez, M.T., Garcia-Navarro, I., Lahuerta, J.J., González, M. & San Miguel, J.F. (2008) Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood, 112, 2709-2712.
9. Vannucchi, A.M., Ficarra, G., Antonioli, E. & Bosi, A. (2005) Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. British Journal of Haematology, 128, 738.
10. Wang, L.H., Yang, X.Y., Zhang, X., Huang, J., Hou, J., Li, J., Xiong, H., Mihalic, K., Zhu, H., Xiao, W. & Farrar, W.L. (2004) Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells. Immunity, 20, 205-218.